單克隆抗體是一個(gè)多學(xué)科的雜志，致力于藝術(shù)和科學(xué)抗體的研究和發(fā)展。該雜志具有強(qiáng)大的科學(xué)和醫(yī)學(xué)重點(diǎn)，但也努力為更廣泛的讀者服務(wù)。因此，科學(xué)家、臨床研究人員、醫(yī)生以及更廣泛的mAb社區(qū)都對(duì)這些文章感興趣，包括我們的讀者，他們涉及技術(shù)轉(zhuǎn)讓、法律問題、投資、戰(zhàn)略規(guī)劃和治療的監(jiān)管。mAbs出版相關(guān)的和及時(shí)的原始研究，以及權(quán)威的綜述、評(píng)論和觀點(diǎn)，為mAbs中提出的工作和其他地方發(fā)表的關(guān)鍵結(jié)果提供上下文。原始研究論文可能涵蓋抗體領(lǐng)域的所有重要主題，包括對(duì)非抗體為基礎(chǔ)的靶向蛋白的研究。歡迎對(duì)抗體研發(fā)的任何方面進(jìn)行評(píng)論、評(píng)論和展望。相關(guān)主題包括(但不限于)：抗體工程及選擇目標(biāo)與癌癥、免疫介導(dǎo)性疾病和其他疾病相關(guān)抗體的非臨床研究，如作用機(jī)理研究、動(dòng)物安全性和有效性研制造業(yè)臨床研究抗體療法的監(jiān)管審查審批后的主題，如定價(jià)、報(bào)銷和市場(chǎng)專利抗體療法的新興市場(chǎng)，包括中國(guó)和印度所有提交的稿件都要經(jīng)過編輯人員的初步評(píng)估，如果發(fā)現(xiàn)適合進(jìn)一步考慮，稿件將由獨(dú)立的、匿名的專家評(píng)審人員提交給同行評(píng)審。所有同行評(píng)審都是單盲的。提交請(qǐng)?jiān)L問http://www.editorialmanager.com/mabs

mAbs is a multi-disciplinary journal dedicated to the art and science of antibody research and development. The journal has a strong scientific and medical focus, but also strives to serve a broader readership. The articles are thus of interest to scientists, clinical researchers, and physicians, as well as the wider mAb community, including our readers involved in technology transfer, legal issues, investment, strategic planning and the regulation of therapeutics. mAbs publishes relevant and timely original research, as well as authoritative overviews, commentary and perspectives providing context for the work presented in mAbs and for key results published elsewhere. Original research papers may cover all topics important in the antibody field, including studies of targeted proteins that are not antibody-based. Reviews, commentaries and perspectives on any aspect of antibody R&D are welcome. Relevant topics include (but are not be limited to): Antibody engineering and selection Targets relevant to cancer, immune-mediated disorders, and other diseasesNon-clinical studies of antibodies, e.g., mechanism of action studies, safety and efficacy studies in animalsManufacturingClinical studiesRegulatory review of antibody therapeuticsPost-approval topics, e.g., pricing, reimbursement and marketsPatentsEmerging markets for antibody therapeutics, including China and IndiaAll submitted manuscripts are subjected to initial evaluation by the editorial staff, and, if found suitable for further consideration, manuscripts are sent to peer review by independent, anonymous expert referees. All peer review is single blind. Submission is online at http://www.editorialmanager.com/mabs